Latest News About Prostate Cancer

Here are the latest established highlights on prostate cancer, based on current public reporting up to 2026:

• New treatments and trials continue to refine options for metastatic and castration-resistant prostate cancer, including combination regimens and targeted therapies that may extend progression-free and overall survival in specific patient groups. For example, triplet regimens and PARP inhibitors have been repeatedly explored in recent years, with ongoing trials further delineating who benefits most.[1][2]

• Advances in diagnostics and risk stratification are expanding the toolbox beyond PSA alone. Tests such as PHI, 4Kscore, and urine-based biomarkers (Sentinel PCa, IsoPSA) are being evaluated to better distinguish clinically significant disease from indolent cancers, potentially reducing unnecessary biopsies and guiding treatment decisions.[2]

• Research into bone metastasis and the biology of spread is receiving attention, including collaborative funding efforts focused on understanding why tumors spread to bone and how to interrupt that process, with implications for both prostate and breast cancers.[3]

• News outlets and health organizations continue to cover high-profile cases and evolving management strategies, including targeted imaging and localized treatments, though outcomes can vary by stage, biomarker status, and patient health.[4]

• For ongoing, high-quality updates, consider sources that summarize clinical trial outcomes, practice guideline updates, and new diagnostic tests. Reputable outlets include major cancer organizations and medical journals, which regularly publish trial results and reviews that inform standard-of-care practice.[5][2]

If you’d like, I can fetch the most recent individual articles or create a brief digest focused on a specific aspect (e.g., treatments for metastatic hormone-sensitive disease, PSMA-targeted therapies, or new diagnostic biomarkers) and provide direct summaries with citations.